Tag: share

– Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. Makary, M.D., M.P.H. –

DEERFIELD, Ill, June 06, 2025 (GLOBE NEWSWIRE) -- BAB, Inc. (OTCQB: BABB), today announced that its Board of Directors has declared a quarterly distribution of one cent ($0.01) per share, payable on July 14, 2025 to shareholders of record as of June 26, 2025.

Receives Notice of Failure to File Interim Financial Statements in Violation of Nasdaq Listing Rules

WALTHAM, Mass. and STOCKHOLM, June 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi^® (STO:SOBI) today presented new data from the open-label period of the Phase 3 VALIANT study, investigating EMPAVELI^® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The data were presented as part of a late-breaking session at the European Renal Association (ERA) Congress.

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

INDIANAPOLIS, June 06, 2025 (GLOBE NEWSWIRE) -- Hurco Companies, Inc. (Nasdaq: HURC) today reported results for the second fiscal quarter ended April 30, 2025. Hurco recorded a net loss of $4,063,000, or $0.62 per diluted share, for the second quarter of fiscal year 2025, which included a non-cash tax valuation allowance of $1,270,000 recorded in provision for income taxes. This net loss of $4,063,000 for the second quarter of fiscal 2025 compared to a net loss of $3,922,000, or $0.61 per diluted share, for the corresponding period in fiscal year 2024. For the first six months of fiscal year 2025, Hurco reported a net loss of $8,383,000, or $1.29 per diluted share, compared to a net loss of $5,570,000, or $0.86 per diluted share, for the corresponding period in fiscal year 2024. The net loss for the first six months of fiscal 2025 included $3,655,000 non-cash tax valuation allowance recorded in provision for income taxes.